Literature DB >> 10395874

The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains.

S A Rubin1, P J Snoy, K E Wright, E G Brown, P Reeve, J A Beeler, K M Carbone.   

Abstract

Wild type mumps viruses are highly neurotropic and a frequent cause of aseptic meningitis in unvaccinated humans. To test whether attenuated mumps viruses used in the manufacture of mumps vaccines have neurovirulent properties, a monkey neurovirulence safety test (MNVT) is performed. However, results with several mumps virus MNVTs have raised questions as to whether the test can reliably discriminate neurovirulent from nonneurovirulent mumps virus strains. Here, various mumps virus strains representing a wide range of neuropathogenicity were tested in a standardized MNVT. A trend of higher neurovirulence scores was observed in monkeys inoculated with wild type mumps virus versus vaccine strains, although differences were not statistically significant. Results indicated the need for further examination and refinement of the MNVT or for development of alternative MNVTs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395874     DOI: 10.1086/314905

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Function of small hydrophobic proteins of paramyxovirus.

Authors:  Rebecca L Wilson; Sandra M Fuentes; Ping Wang; Erica C Taddeo; Alicia Klatt; Andrew J Henderson; Biao He
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors.

Authors:  Gyoung Nyoun Kim; Kunyu Wu; Jiho Patrick Hong; Zain Awamleh; C Yong Kang
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

4.  High-throughput automated image analysis of neuroinflammation and neurodegeneration enables quantitative assessment of virus neurovirulence.

Authors:  Olga A Maximova; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2010-08-03       Impact factor: 3.641

5.  Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans.

Authors:  S A Rubin; M Pletnikov; R Taffs; P J Snoy; D Kobasa; E G Brown; K E Wright; K M Carbone
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Gene-specific contributions to mumps virus neurovirulence and neuroattenuation.

Authors:  Christian J Sauder; Cheryl X Zhang; Laurie Ngo; Kellie Werner; Ken Lemon; W Paul Duprex; Tahir Malik; Kathryn Carbone; Steven A Rubin
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

7.  The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence.

Authors:  Ken Lemon; Bertus K Rima; Stephen McQuaid; Ingrid V Allen; W Paul Duprex
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

8.  Infection of mice, ferrets, and rhesus macaques with a clinical mumps virus isolate.

Authors:  Pei Xu; Zhixiang Huang; Xiudan Gao; Frank J Michel; Gwen Hirsch; Robert J Hogan; Kaori Sakamoto; Wenzhe Ho; Jianguo Wu; Biao He
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

9.  A single nucleotide change in the mumps virus F gene affects virus fusogenicity in vitro and virulence in vivo.

Authors:  Tahir Malik; Christian Sauder; Candie Wolbert; Cheryl Zhang; Kathryn M Carbone; Steven Rubin
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

10.  Molecular differences between two Jeryl Lynn mumps virus vaccine component strains, JL5 and JL2.

Authors:  Phil Chambers; Bert K Rima; W Paul Duprex
Journal:  J Gen Virol       Date:  2009-08-05       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.